Biopolymer strategy for the treatment of Wilson's disease

Confined copper depletion via a hydrogel platform for reversing dabrafenib/cetuximab resistance in BRAFV600E-mutant colorectal cancer

BRAFV600E-mutant colorectal cancer (CRC) is resistant to most first-line therapeutics, including the BRAF inhibitor dabrafenib and epidermal growth factor receptor (EGFR) inhibitor cetuximab. Although copper depletion shows promise in reversing dabrafenib/cetuximab resistance in BRAFV600E-mutant CRC, its application is limited by the potential for excessive copper depletion in non-tumor objects. In this study, we have developed a hydrogel platform for confined copper depletion in BRAFV600E-mutant CRC cells, which effectively reverses dabrafenib/cetuximab resistance and enhancing therapeutic efficiency. The hydrogel platform enables precise intracellular copper depletion through localized administration, acidity-triggered drug release, and oxidized activation of a copper prochelator. The dosage of this prochelator is 37.5 μg/kg in mouse models, which is significantly lower than the commonly used tetrathiomolybdate. Furthermore, both dabrafenib and the prochelator are preloaded into acid-responsive nanoparticles before being embedded in the hydrogel matrix to facilitate efficient endocytosis and acid-activatable drug release. Confined copper depletion inhibits MEK1 signaling and suppresses the MAPK signaling pathway when combined with BRAF and EGFR inhibitors. Moreover, the hydrogel platform inhibits tumor growth and prolongs survival in subcutaneous and postsurgical models of BRAFV600E-mutant CRC. This study provides an innovative strategy for overcoming dabrafenib/cetuximab resistance in BRAFV600E-mutant CRC through precise intracellular copper depletion.

All-in-one strategy for the nano-engineering of paper-based bifunctional fluorescent platform for robustly-integrated real-time monitoring of food and drinking-water safety

Cu2+ contamination and food spoilage raise food and drinking water safety issues, posing a serious threat to human health. Besides, Cu2+ and H2S levels indicate excess Cu2+-caused diseases and protein-containing food spoilage. Herein, a coumarin-containing bifunctional paper-based fluorescent platform integrated with a straightforward smartphone color recognition app is developed by an all-in-one strategy. The proposed fluorescent materials can simultaneously detect Cu2+ and H2S for on-demand food and drinking water safety monitoring at home. Specifically, a coumarin-derived fluorescence sensor (referred to as CMIA) with a low detection limit (0.430 μM) and high-selectivity/-sensitivity for Cu2+ is synthesized through a simple one-step route and then loaded onto commercially used cellulose fiber filter paper to engineer a biomass-based fluorescent material (CMIA-FP). The CMIA-FP offers user-friendly, high-precision, fast-responsive, and real-time visual monitoring of Cu2+. Moreover, CMIA forms a chemically stable complex with Cu2+, loaded onto filter paper to prepare another biomass-based fluorescent platform (CMIA-CU-FP) for visual real-time monitoring of H2S. Based on the exquisite composition design, the proposed dual-function paper-based fluorescent materials equipped with a smartphone color recognition program concurrently realize fast, accurate, and easy real-time monitoring of Cu2+ in drinking water and H2S in chicken breast-/shrimp-spoilage, demonstrating an effective detection strategy for the Cu2+ and H2S monitoring and presenting the new type of biomass-based platforms for concentrated reflection of drinking water and food safety.

Cuproptosis: mechanisms and links with cancers

Cuproptosis was a copper-dependent and unique kind of cell death that was separate from existing other forms of cell death. The last decade has witnessed a considerable increase in investigations of programmed cell death, and whether copper induced cell death was an independent form of cell death has long been argued until mechanism of cuproptosis has been revealed. After that, increasing number of researchers attempted to identify the relationship between cuproptosis and the process of cancer. Thus, in this review, we systematically detailed the systemic and cellular metabolic processes of copper and the copper-related tumor signaling pathways. Moreover, we not only focus on the discovery process of cuproptosis and its mechanism, but also outline the association between cuproptosis and cancers. Finally, we further highlight the possible therapeutic direction of employing copper ion ionophores with cuproptosis-inducing functions in combination with small molecule drugs for targeted therapy to treat specific cancers.

Pharmaceutical and drug delivery applications of chitosan biopolymer and its modified nanocomposite: A review

Due to their improved structural and functional properties as well as biocompatibility, biodegradability, and nontoxicity, chitosan and its nanoparticles are currently grasping the interest of researchers. Although numerous attempts have been made to apply chitosan and its derivatives to biological applications, few have reported in achieving its pharmacological and drug delivery. The goal of the current work is to provide a summary of the chitosan biopolymer's physical, chemical, and biological properties as well as its synthesis of nanoparticles and characterization of its modified nanocomposites. The drug delivery method and pharmaceutical applications of chitosan biopolymer and its modified nanocomposites are examined in further detail in this research. We will introduce also about the most current publications in this field of study as well as its recent expansion.

Chelators for Treatment of Iron and Copper Overload: Shift from Low-Molecular-Weight Compounds to Polymers

Iron and copper are essential micronutrients needed for the proper function of every cell. However, in excessive amounts, these elements are toxic, as they may cause oxidative stress, resulting in damage to the liver and other organs. This may happen due to poisoning, as a side effect of thalassemia infusion therapy or due to hereditary diseases hemochromatosis or Wilson's disease. The current golden standard of therapy of iron and copper overload is the use of low-molecular-weight chelators of these elements. However, these agents suffer from severe side effects, are often expensive and possess unfavorable pharmacokinetics, thus limiting the usability of such therapy. The emerging concepts are polymer-supported iron- and copper-chelating therapeutics, either for parenteral or oral use, which shows vivid potential to keep the therapeutic efficacy of low-molecular-weight agents, while avoiding their drawbacks, especially their side effects. Critical evaluation of this new perspective polymer approach is the purpose of this review article.

Wilson's disease: update on pathogenesis, biomarkers and treatments

Wilson's disease is an autosomal-recessive disorder of copper metabolism caused by mutations in ATP7B and associated with neurological, psychiatric, ophthalmological and hepatic manifestations. Decoppering treatments are used to prevent disease progression and reduce symptoms, but neurological outcomes remain mixed. In this article, we review the current understanding of pathogenesis, biomarkers and treatments for Wilson's disease from the neurological perspective, with a focus on recent advances. The genetic and molecular mechanisms associated with ATP7B dysfunction have been well characterised, but despite extensive efforts to identify genotype-phenotype correlations, the reason why only some patients develop neurological or psychiatric features remains unclear. We discuss pathological processes through which copper accumulation leads to neurodegeneration, such as mitochondrial dysfunction, the role of brain iron metabolism and the broader concept of selective neuronal vulnerability in Wilson's disease. Delayed diagnoses continue to be a major problem for patients with neurological presentations. We highlight limitations in our current approach to making a diagnosis and novel diagnostic biomarkers, including the potential for newborn screening programmes. We describe recent progress in developing imaging and wet (fluid) biomarkers for neurological involvement, including findings from quantitative MRI and other neuroimaging studies, and the development of a semiquantitative scoring system for assessing radiological severity. Finally, we cover the use of established and novel chelating agents, paradoxical neurological worsening, and progress developing targeted molecular and gene therapy for Wilson's disease, before discussing future directions for translational research.